Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.62 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11968772 | 0.88 | KCNH2 (0.61) | KCNH2POLBCNR1CNR2 | |
| SCHEMBL4782432 | 0.86 | KCNH2 (0.58) | KCNH2TSHRPOLBHPGDCNR1 | |
| SCHEMBL12002183 | 0.84 | KCNH2 (0.53) | KCNH2TSHRPOLBHPGDCNR1 | |
| SCHEMBL2799380 | 0.84 | KCNH2 (0.53) | KCNH2TSHRPOLBHPGDCNR1 | |
| SCHEMBL11968773 | 0.82 | KCNH2 (0.56) | KCNH2TSHRPOLBHPGDCNR1 | |
| SCHEMBL12002336 | 0.82 | KCNH2 (0.64) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL12002251 | 0.81 | KCNH2 (0.63) | KCNH2KCNQ1CACNA1CTP53 | |
| SCHEMBL2799419 | 0.81 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL12002105 | 0.81 | KCNH2 (0.65) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL12002332 | 0.80 | KCNH2 (0.57) | KCNH2KCNQ1CACNA1CTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | KCNH2 525/4885KCNQ1 240/4885CACNA1C 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.